Loading…
Guardant Health, Inc. is projected to rise to $202.08 by 2027, a +58% move from its current price of $127.51. GH is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $123.42 | $127.51 | $131.73 | 0.00% |
| May 30 | $121.76 | $127.50 | $133.52 | 0.00% |
| May 31 | $120.50 | $127.50 | $134.91 | -0.01% |
| Jun 1 | $119.45 | $127.50 | $136.09 | -0.01% |
| Jun 2 | $118.53 | $127.50 | $137.14 | -0.01% |
| Jun 3 | $117.71 | $127.49 | $138.10 | -0.01% |
| Jun 4 | $116.95 | $127.49 | $138.98 | -0.02% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $116.95 | $127.49 | $138.98 | -0.02% |
| Week 2 | $112.83 | $127.47 | $144.02 | -0.03% |
| Week 3 | $109.76 | $127.45 | $148.00 | -0.05% |
| Week 4 | $107.24 | $127.43 | $151.44 | -0.06% |
| Week 5 | $105.06 | $127.41 | $154.53 | -0.08% |
| Week 6 | $103.13 | $127.40 | $157.38 | -0.09% |
| Week 7 | $101.38 | $127.38 | $160.04 | -0.11% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Guardant Health, Inc. is a precision oncology company that provides blood and tissue tests, and data sets in the United States and internationally. Its portfolio includes Guardant360 CDx test, Guardant360 Liquid test (which measures 740+ genes and supports all guideline-recommended biomarkers), Guardant Reveal test, and Guardant360 Tissue test.
It also offers Shield blood test for colorectal cancer screening, GuardantINFINITY, GuardantOMNI, GuardantINFORM, and GuardantConnect, plus the Smart Platform delivering multiomic insights. The company provides development services and has a strategic collaboration with Nuvalent, Inc. for oncology drug development.
Guardant Health was incorporated in 2011 and is headquartered in Palo Alto, California.
Guardant Health, Inc. (GH) is a healthcare stock currently priced at $127.51 with a market cap of $16.91B, ranking 645.
The latest forecast points to a long-run bullish price path, with a 2026 average of $127.51 and rising to $306.14 by 2030 and to $2,156.24 in 2050.
The forecast also shows an upside trajectory across the years, with higher max values and progressively stronger ROI expected beyond 2030. In 2040 the average is forecast at $992.03 and by 2050 the max reaches $4,278.59, underscoring a substantial long-term upside.
Overall, near-term volatility is indicated by the 30-day range and mixed early-year signals, while the longer horizon is characterized by a bullish outlook.
A major floor 46.4% below — a decisive break under it would weaken the trend.
The nearest floor, 34.8% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 23.2% above — clearing it would confirm fresh momentum.
Key GH support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GH market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $119.86 | Buy | $118.74 | Buy |
| MA 10 | $108.52 | Buy | $111.68 | Buy |
| MA 20 | $100.04 | Buy | $104.06 | Buy |
| MA 50 | $92.66 | Buy | $97.38 | Buy |
| MA 100 | $98.01 | Buy | $94.65 | Buy |
| MA 200 | $88.41 | Buy | $86.39 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 81.78 | Sell |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 184.82 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 3.20 | Buy |
| ROC (12) | 33.24 | Buy |
| Bollinger %B (20,2) | 1.06 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.76 | Buy |
| Awesome (5,34) | 25.28 | Buy |
| Ultimate (7,14,28) | 93.66 | Sell |
| Momentum (10) | 27.57 | Buy |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 127.59 | Sell |
| ADX (14) | 27.71 | Buy |
| ATR (14) | 3.18 | Info |
The near-term technical picture is bullish, with RSI14 at 80 and sentiment labeled BULLISH.
The SMA50 stands at $92.66 and the SMA200 at $88.41, indicating the shorter-term trend is above longer-term averages. A key support level is listed at $83.09 and a resistance at $127.51.
For the immediate trading window, the 30-day range runs from $102.84 to $158.09.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $78.60 | $127.51 | $198.75 | 0% | Neutral | |
| $157.25 | $202.08 | $276.83 | +58% | Bullish | |
| $173.06 | $229.89 | $328.25 | +80% | Bullish | |
| $186.76 | $255.10 | $376.33 | +100% | Bullish | |
| $218.61 | $306.14 | $464.20 | +140% | Bullish | |
| $223.87 | $320.73 | $498.15 | +152% | Bullish | |
| $252.59 | $369.70 | $586.68 | +190% | Bullish | |
| $338.22 | $505.13 | $817.34 | +296% | Bullish | |
| $373.12 | $568.09 | $935.81 | +346% | Bullish | |
| $409.72 | $635.46 | $1,064.29 | +398% | Bullish | |
| $587.46 | $992.03 | $1,780.70 | +678% | Bullish | |
| $1,098.34 | $2,156.24 | $4,278.59 | +15.9x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $78.60 | $127.51 | $150.80 | +0.00% |
| June 2026 | $110.25 | $130.03 | $157.40 | +1.98% |
| July 2026 | $106.82 | $127.26 | $156.53 | -2.13% |
| August 2026 | $108.66 | $130.48 | $162.46 | +2.53% |
| September 2026 | $114.73 | $138.67 | $174.38 | +6.27% |
| October 2026 | $116.92 | $142.17 | $180.40 | +2.52% |
| November 2026 | $118.36 | $144.70 | $185.05 | +1.78% |
| December 2026 | $125.55 | $154.27 | $198.75 | +6.61% |
Click any year to see its month-by-month GH forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, GH is projected to trade between $78.60 and $198.75, averaging $127.51 — a potential gain of 0% from today's $127.51. Price action looks broadly range-bound.
Guardant Health, Inc.'s 2027 outlook centres on $202.08, within a $157.25 to $276.83 range. That is up +58% on the projected 2026 average. That marks a +58% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, GH could reach as high as $328.25, with a base case around $229.89 and support toward $173.06 — roughly +80% from $127.51. Momentum favours further upside here.
Expect GH to range from $186.76 to $376.33 through 2029. The $255.10 average target implies a +100% move from current prices. That is up +11% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The GH price prediction for 2030 points to an average of $306.14 (low $218.61, high $464.20) — a potential gain of +140% on today's $127.51. Momentum favours further upside here.
In 2031, GH is projected to trade between $223.87 and $498.15, averaging $320.73 — a potential gain of +152% from today's $127.51. That is up +5% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Guardant Health, Inc.'s 2032 outlook centres on $369.70, within a $252.59 to $586.68 range. That is up +15% on the projected 2031 average. That marks a +190% change versus current levels. Momentum favours further upside here.
By 2033, GH could reach as high as $817.34, with a base case around $505.13 and support toward $338.22 — roughly +296% from $127.51. Buyers look set to stay in control over this stretch.
Expect GH to range from $373.12 to $935.81 through 2034. The $568.09 average target implies a +346% move from current prices. That is up +12% on the projected 2033 average. Momentum favours further upside here.
The GH price prediction for 2035 points to an average of $635.46 (low $409.72, high $1,064.29) — a potential gain of +398% on today's $127.51. Buyers look set to stay in control over this stretch.
In 2040, GH is projected to trade between $587.46 and $1,780.70, averaging $992.03 — a potential gain of +678% from today's $127.51. That is up +56% on the projected 2035 average. Momentum favours further upside here.
Guardant Health, Inc.'s 2050 outlook centres on $2,156.24, within a $1,098.34 to $4,278.59 range. That is up +117% on the projected 2040 average. That marks a +15.9x change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in GH today (≈ 7.842522 GH) could be worth
$16,910.38
+$15,910.38 (+1591%) by 2050 · US Dollar
Based on the average projected GH price of $2,156.24 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GHwould be worth at today's price.
$1,000 invested in GH on May 27, 2025 (≈ 25.529743 GH) would be worth
$3,255.3
+$2,255.3 (+225.5%) today · 3.26× · US Dollar
Based on a GH entry price of $39.17 vs. today's $127.51.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $114.97 | $1,109.07 | +10.9% |
| 1 month ago | $88.5 | $1,440.79 | +44.1% |
| 3 months ago | $97.97 | $1,301.52 | +30.2% |
| 6 months ago | $108.42 | $1,176.07 | +17.6% |
| 1 year ago | $39.17 | $3,255.3 | +225.5% |
| All time (5.0y) ago | $119.12 | $1,070.43 | +7.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GH forecast.
Our base-case forecast reaches $260.00 around 2030.
Implied market cap at $260.00: $34.48B
The multi-year forecast paints a clear bullish trajectory through the rest of the decade and into the 2040s and beyond. In 2027 the average is $202.08 with ROI 58.5 and bullish sentiment, rising from the 2026 baseline of $127.51 (ROI 0; sentiment Neutral).
From 2028 to 2035 the averages rise from $229.89 to $635.46, with ROIs advancing from 80.3 to 398.4 and persistent bullish sentiment. Notably, 2030 is forecast at an average of $306.14 with ROI 140.1, and 2035 at $635.46 with ROI 398.4.
The forecast continues to an average of $992.03 in 2040 (ROI 678) and $2,156.24 in 2050 (ROI 1591), with the 2050 maximum forecast at $4,278.59. These are forward-looking estimates and not guarantees, and actual results may vary.
Tap a question to reveal the answer.
The forecast shows an average price of $306.14, with a min of $218.61 and a max of $464.20, and a ROI of 140.1; sentiment is BULLISH.
The forecast shows bullish sentiment across many years, with 2027 avg $202.08 (ROI 58.5), 2028 avg $229.89 (ROI 80.3), 2029 avg $255.10 (ROI 100.1), and 2030 avg $306.14 (ROI 140.1). Note that 2026 shows Neutral sentiment and ROI 0, reflecting near-term uncertainty.
Yes. The forecast max values include $1,064.29 (2035), $1,780.70 (2040), and $4,278.59 (2050), illustrating substantial upside potential over the long term.
Current price is $127.51 and market cap is $16.91B.
RSI(14) is 80. The 50-day and 200-day moving averages are $92.66 and $88.41 respectively, with support at $83.09 and resistance at $127.51. The 30-day range is $102.84 to $158.09.
Guardant Health, Inc. Community Discussion
0Share your Guardant Health, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.